Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901752 | 0.88 | ALDH1A1 (0.39) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL12191344 | 0.88 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL13439127 | 0.88 | TSHR (0.32) | TSHRALDH1A1 | |
| SCHEMBL24452970 | 0.84 | ALDH1A1 (0.32) | TSHRALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL19910088 | 0.84 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13237585 | 0.79 | TSHR (0.30) | TSHR | |
| SCHEMBL2141255 | 0.77 | TSHR (0.50) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL2571985 | 0.77 | ALDH1A1 (0.34) | TSHRALDH1A1MAPK1 | |
| SCHEMBL14350899 | 0.77 | TSHR (0.38) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL14517851 | 0.76 | TSHR (0.44) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637526-B1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7754903-B2 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKUYAMA CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKYUYAMA CORPORATION (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637526-A1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | PFN1, FSCN1, PFDN1 | TSHR 3361/4885ALDH1A1 50/4885MAPK1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.